CN101606960B - Oral medicinal composition - Google Patents
Oral medicinal composition Download PDFInfo
- Publication number
- CN101606960B CN101606960B CN 200810016954 CN200810016954A CN101606960B CN 101606960 B CN101606960 B CN 101606960B CN 200810016954 CN200810016954 CN 200810016954 CN 200810016954 A CN200810016954 A CN 200810016954A CN 101606960 B CN101606960 B CN 101606960B
- Authority
- CN
- China
- Prior art keywords
- taurine
- radix isatidis
- granule
- extract
- make
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 102
- 229960003080 taurine Drugs 0.000 claims abstract description 48
- 239000010231 banlangen Substances 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 23
- 229940126701 oral medication Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 5
- 206010046306 Upper respiratory tract infection Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 241000334160 Isatis Species 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 39
- 208000024891 symptom Diseases 0.000 description 17
- 206010022000 influenza Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000008961 swelling Effects 0.000 description 10
- 210000003026 hypopharynx Anatomy 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 208000007117 Oral Ulcer Diseases 0.000 description 6
- 208000002399 aphthous stomatitis Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 208000036071 Rhinorrhea Diseases 0.000 description 5
- 206010039101 Rhinorrhoea Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960005224 roxithromycin Drugs 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BITDLWAQPKSXTF-UHFFFAOYSA-M 1-[(3-nitrophenyl)methoxymethyl]pyridin-1-ium;chloride Chemical compound [Cl-].[O-][N+](=O)C1=CC=CC(COC[N+]=2C=CC=CC=2)=C1 BITDLWAQPKSXTF-UHFFFAOYSA-M 0.000 description 1
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MKXZASYAUGDDCJ-NJAFHUGGSA-N dextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-NJAFHUGGSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960005389 moroxydine Drugs 0.000 description 1
- 229960002581 moroxydine hydrochloride Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 1
- 229950006796 spiramycin ii Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an oral medicinal composition for treating cold, which is characterized by comprising isatis/indigowoad leaf and taurine; through synergistic action of the isatis/indigowoad leaf and the taurine, the oral medicinal composition can achieve the treatment effects of clearing heat and resolving toxin, removing inflammation, resisting virus, strengthening immunity and the like. The oral medicinal composition is convenient to take and has quick response and high curing rate in treating upper respiratory tract infection, dental ulcer and other diseases caused by cold and other factors. The medicinal composition can be prepared into any oral preparation.
Description
Technical field
The present invention relates to a kind of flu and the upper respiratory tract infection that causes because of factors such as flu and combination of oral medication of oral ulcer for the treatment of, the upper respiratory tract infection that the factors such as treatment flu of a kind of Radix Isatidis/Folium Isatidis and taurine co-action of relating in particular to cause.
Background technology
Flu is a kind of common clinical, frequently-occurring disease, and morbidity is all arranged throughout the year, can fall ill for each person every year for several times.Clinical symptoms has symptoms such as sneeze, rhinorrhea, dry pharynx, oral ulcer, itching of the throat, burning sensation and pain.In the prior art, the medicine for the treatment of flu has Western medicine, as to acetamido phenol, compound amino romilar, Huanghai Sea common cold tablet etc.; Chinese medicine is also arranged, stick up detoxifying pills etc. as Radix Isatidis, Folium Isatidis, compound recipe Flos Lonicerae, antelope.The medicine Western medicine for the treatment of dry pharynx, itching of the throat or burning sensation and pain has antibiotics, and Chinese medicine has Waterelon Frost Lozenges etc.The characteristics of western medicine are that doing well,improving is very fast, but untoward reaction rate height, and cure the symptoms, not the disease, the state of an illness easily recurs.The characteristics for the treatment of by Chinese herbs are that effect is gentle, treating both the principal and secondary aspects of a disease, and the untoward reaction rate is low.
Publication number is the combination of oral medication that the patent of invention of CN1813849A discloses the treatment flu that contains Radix Isatidis and taurine, and disclosed medicament composing prescription is: Radix Isatidis 1000g-1500g, taurine: 30g-50g.This invention does not disclose effective dose and the instructions of taking of pharmaceutical preparation.
The inventor is through research repeatedly, and the checking repeatedly by clinical experiment, by the synergism of Radix Isatidis and taurine, has improved the therapeutic effect of compositions greatly, has obtained beyond thought clinical therapeutic efficacy.
The objective of the invention is to overcome existing deficiency for the treatment of the medicine of flu, to people provide that a kind of dose is little, determined curative effect, instant effect, medicine that the untoward reaction rate is low, medicine of the present invention improves the immunity of human body especially to flu and because catch a cold caused upper respiratory tract infection and oral ulcer have beyond thought therapeutic effect in the treatment flu.
Technical scheme
Combination of oral medication of the present invention selects Radix Isatidis/Folium Isatidis and taurine to make up, and makes each ingredient effect produce synergism, thereby can treat flu effectively and because of caused by factors upper respiratory tract infection such as flu and oral ulcer etc.
Wherein, selecting Radix Isatidis or Folium Isatidis is because the two belongs to root and the leaf of same plant, be the traditional Chinese medicine of China, put down in writing according to " Chinese medicine dictionary ", Radix Isatidis or Folium Isatidis have heat clearing away, detoxifcation, the effect of removing heat from blood, sore-throat relieving is rotted for epidemic febrile disease heating, a speckle, anemopyretic cold, swelling throat, for herpes simplex keratitis, oral ulcer, acute pharyngitis, mumps etc. good treatment and preventive effect is arranged also.
According to the record of the Pharmacopoeia of the People's Republic of China, the Radix Isatidis bitterness is cold, GUIXIN, stomach warp.Has heat-clearing and toxic substances removing, removing heat from blood sore-throat relieving function.Be used for noxious dampness and send out speckle, crimson tongue is purple dark, mumps, larynx illness, scarlet fever, major part pestilence, erysipelas, carbuncle; Folium Isatidis property bitterness is flat, returns large intestine, Liver Channel.Have heat-clearing and toxic substances removing, invigorate blood circulation, the function of dispeling the wind.Be used for abdominalgia with intestinal abscess, amenorrhea dysmenorrhea, rheumatism illness pain, tumbling and swelling.
Taurine is called taurine or 2-aminoethyl sulfonic acid again, select taurine to be because in recent years both at home and abroad the scientist taurine has been carried out deep research from biochemistry, pharmacology, nutrition, aspect such as clinical, consistently think it: one can promote the differentiation and development of infant, children brain cell, keep cell membrane, particularly retina normal physiological function, to improving brain function, suppress and treat alzheimer disease to play an important role; Two can reduce cell mitochondrial lipid peroxidation after the strenuous exercise, keep SOD (superoxide dismutase) activity, keep GSH (reduced form paddy Guang peptide) content, thereby regulate metabolism and the calcium ion concentration of lipid within endothelial cells and phospholipid, recovery physical after the strenuous exercise is played an important role; Three can regulate hemocyte and plasma fraction, keep the normal immunologic function of blood; Four can the endocrine regulation system, the enhancing human body immunity function; Five energy regulate body temperature have antipyretic-antalgic, effects such as antiinflammatory, rheumatism, convulsion, anti-blood glucose, blood pressure lowering; Six pairs of hepatocyte injury have protective effect.
To be the inventor through a large amount of groping sum up drug dose of the present invention draws.Technical scheme of the present invention is:
A kind of combination of oral medication contains Radix Isatidis/Folium Isatidis and taurine.Wherein, Radix Isatidis/Folium Isatidis can be selected crude drug or its extract.
Combination of oral medication of the present invention contains Radix Isatidis 5-25 weight portion, taurine 1 weight portion.
Be preferably Radix Isatidis 7-20 weight portion, taurine 1 weight portion.
Radix Isatidis 7-15 weight portion more preferably, taurine 1 weight portion
Combination of oral medication of the present invention can also be to contain 5-70 weight portion Folium Isatidis, the compositions of 1 weight portion taurine.
Be preferably Folium Isatidis 7-60 weight portion, taurine 1 weight portion.
Folium Isatidis 8-50 weight portion more preferably, taurine 1 weight portion.
Folium Isatidis 10-40 weight portion more preferably, taurine 1 weight portion.
Combination of oral medication of the present invention is when the adult is oral, in the compositions of unit dose, with dose taurine clinical effectiveness ideal between 0.8 gram restrains to 2.0.
Combination of oral medication of the present invention can adopt the conventional preparation method of Chinese medicine preparation to make any conventional oral formulations.
For example: can be with Radix Isatidis or Folium Isatidis pulverize, and make powder after taurine mixes and take after mixing it with water; Also can with Radix Isatidis or Folium Isatidis with conventional method with water extraction after; or behind the water extract-alcohol precipitation; concentrated extracting solution; and then mix with taurine; add the required various conventional adjuvant of preparation different dosage form; be prepared into any peroral dosage form commonly used as excipient, disintegrating agent, lubricant etc. with the method for Chinese medicinal of routine, as pill, tablet, granule, capsule, oral liquid etc.
Can also be with Radix Isatidis or Folium Isatidis pulverize, and make powder after taurine mixes and take after mixing it with water; Also can with Radix Isatidis or Folium Isatidis with conventional method with water extraction after; the condensed water extracting solution; and then mix with taurine; be prepared into oral liquid; can also concentrate Radix Isatidis or Folium Isatidis extracting solution; be prepared into dry extract, pulverize the back and mix with taurine, be prepared into oral formulations such as pill, granule, capsule.
Beneficial effect
Medicine of the present invention has functions such as heat-clearing and toxic substances removing, antiinflammatory, antiviral, increase immunity, and symptoms such as the laryngopharynx swelling and pain that causes to treatment flu and because of catch a cold caused various symptom and other reasons, oral ulcer have excellent curative.In treating both the principal and secondary aspects of a disease, can also increase the immunologic function of human body, suitable all groups take.The inventor believes that product of the present invention necessarily also has other indications, awaits continuing to finish the present invention by variety of way.
Embodiment
The following examples, test example can illustrate in greater detail the present invention, but not limit the present invention in any form.
Test example 1
The preparation of Radix Isatidis extract
The 10kg Radix Isatidis decocts with water twice, and 2 hours for the first time, 1 hour for the second time, filter decocting liquid twice, filtrate merges, and being concentrated into relative density is 1.20 (50 ℃), adds ethanol and makes content reach 60%, leave standstill and make precipitation, get the supernatant, reclaim ethanol and be concentrated into an amount of.
Embodiment 1
The extract of test example 1 is added an amount of dextrin, make granule, obtain the 1kg extract particles.
Prescription: Radix Isatidis extract granule 700g
Sucrose 8500g
Dextrin 3700g
Taurine 1000g
Preparation technology: take by weighing the Radix Isatidis extract granule 700g of recipe quantity, dextrin 3700g, taurine 1000g crosses 100 mesh sieves, and mix homogeneously adds sucrose 8500g (crossing 100 mesh sieves) again, and 75% ethanol is soft material processed in right amount.
12 mesh sieves are granulated, 55 ℃ of dryings 5 hours, 10 mesh sieve granulate.Make 1000 bags.Every bag contains Radix Isatidis extract 0.7 gram, taurine 0.8 gram.
According to the form below is changed the consumption of Radix Isatidis extract and taurine, and preparation method is with embodiment 1.
| Experimental example | Radix Isatidis extract granule (kg) | Suitable Radix Isatidis crude drug (kg) | Taurine (kg) |
| 2 | 0.7 | 7 | 1.00 |
| 3 | 1.00 | 10 | 1.00 |
| 4 | 1.5 | 15.0 | 1.00 |
| 5 | 2.0 | 20.0 | 1.00 |
| 6 | 0.84 | 8.4 | 1.2 |
| 7 | 1.2 | 12 | 1.2 |
| 8 | 1.8 | 18 | 1.2 |
| 9 | 1.5 | 15.0 | 1.3 |
| 10 | 1.3 | 13.0 | 1.3 |
| 11 | 1.5 | 15.0 | 1.5 |
| 12 | 3.0 | 30.0 | 1.5 |
| 13 | 0.8 | 8.0 | 1.6 |
| 14 | 1.12 | 11.2 | 1.6 |
| 15 | 1.6 | 16.0 | 1.6 |
| 16 | 1.0 | 10.0 | 2.0 |
| 17 | 1.4 | 14.0 | 2.0 |
| 18 | 2.0 | 20.0 | 2.0 |
| 19 | 1.25 | 12.5 | 2.5 |
| 20 | 1.5 | 15.0 | 2.5 |
| 21 | 2.5 | 25.0 | 1.0 |
| 22 | 1.9 | 19.0 | 1.0 |
| 23 | 2.0 | 20.0 | 0.8 |
Embodiment 24,10kg Radix Isatidis are pulverized the back and are crossed 100 mesh sieves, add the 1.5kg taurine, adorn 1000 bags.
The isatis root extract of embodiment 25, test example 1 is concentrated into 10 liters, adds the 1.5kg taurine, and mix homogeneously is packed as 1000, makes oral liquid.
Embodiment 26, Folium Isatidis 1000 grams add suitable quantity of water and decoct twice, and 2 hours for the first time, 1 hour for the second time, filter decocting liquid twice, filtrate merges, and is concentrated into 200ml, adds 30 gram taurines, stirs, and divides to be filled to 20 bottles.(specification Folium Isatidis 50 grams, taurine 1.5 grams)
Embodiment 27
The preparation of Folium Isatidis extract
The 10kg Folium Isatidis decocts with water twice, and 2 hours for the first time, 1 hour for the second time, filter decocting liquid twice, filtrate merges, through concentrated, precipitate with ethanol, solvent evaporated.Add an amount of dextrin then, make the 1kg extract particles.
The preparation of preparation
Prescription: Folium Isatidis extract granule 800g
Sucrose 8500g
Dextrin 3700g
Taurine 1600g
Preparation technology: take by weighing the Folium Isatidis extract granule 800g of recipe quantity, dextrin 3700g, taurine 1600g crosses 100 mesh sieves, and mix homogeneously adds sucrose 8500g (crossing 100 mesh sieves) again, and 75% ethanol is soft material processed in right amount.
12 mesh sieves are granulated, 55 ℃ of dryings 5 hours, 10 mesh sieve granulate.Make 1000 bags.Every bag contains Folium Isatidis extract 0.8 gram, taurine 1.6 grams.
According to the form below is changed the consumption of Folium Isatidis extract and taurine, and preparation method is with embodiment 27.
| Experimental example | Folium Isatidis extract granule (kg) | Suitable Folium Isatidis crude drug (kg) | Taurine (kg) |
| 28 | 1.0 | 10.0 | 1.6 |
| 29 | 1.6 | 16.0 | 1.6 |
| 30 | 3.2 | 32.0 | 1.6 |
| 30 | 4.8 | 48.0 | 1.6 |
| 31 | 6.4 | 64.0 | 1.6 |
| 32 | 1.5 | 15.0 | 1.5 |
| 33 | 3.0 | 30.0 | 1.5 |
| 34 | 4.5 | 45.0 | 1.5 |
| 35 | 6.0 | 60.0 | 1.5 |
| 36 | 6.0 | 60.0 | 1.2 |
| 37 | 4.8 | 48.0 | 1.2 |
| 38 | 3.6 | 36.0 | 1.2 |
| 39 | 2.4 | 24.0 | 1.2 |
| 40 | 1.2 | 12.0 | 1.2 |
| 41 | 7.0 | 70.0 | 1.0 |
| 42 | 6.0 | 60.0 | 1.0 |
| 43 | 5.0 | 50.0 | 1.0 |
| 44 | 4.0 | 40.0 | 1.0 |
| 45 | 3.2 | 32.0 | 0.8 |
| 46 | 4.0 | 40.0 | 0.8 |
| 47 | 1.6 | 16 | 0.8 |
| 48 | 1.2 | 12 | 0.8 |
Test example 2, certain woman, 45 years old, the clerk, have have sore throat, General Symptomies such as dizziness and tinnitus, heating, do not have significantly flu, rhinorrhea, sneeze symptom.Oral administration Folium Isatidis, Roxithromycin, the your letter week ages such as sheet that relieve inflammation or internal heat are not felt any better; posterior vein injection hydrochloric acid clindamycin inj two days (600mg/ days); inefficacy still; after take embodiment 11 compositions (specification: Radix Isatidis 15 gram, taurine 1.5 grams), each bag; three times on the one; first day, mouth and nose heating, exhalation steam sx were recovered after taking medicine 4 days.
Test example 3, certain man, 40 years old, the enterprise technology personnel had sore throat, and did not have significantly flu, rhinorrhea, sneeze symptom.Oral detoxicating tablet of cow-bezoar, Rhizoma Coptidis supernatant sheet, acetylspiramycin etc. are not felt any better, and take embodiment 11 compositionss (specification: Radix Isatidis 15 grams, taurine 1.5 grams), and each bag three times on the one, was recovered after taking medicine 2 days.
Test example 4, certain woman, 36 years old, the flu sneeze, rhinorrhea is with 38 ℃ of fevers.Take the compositions of embodiment 26, every day 3 times, each 1 bottle, remission on the same day is taken medicine and was recovered in 3 days.
Test example 5,, certain boy student, 13 years old, sneeze, cough, laryngopharynx swelling and pain and with the fever symptom, oral Radix Isatidis (specification: every day 3 times 7 grams), take medicine and do not feel any better in 2 days by each 2 bags.Change the compositions of clothes experimental example 3, the second day symptom of taking medicine obviously improved, and temperature recovery is normal, takes medicine recovery from illness 3 days.
Flu patient with severe symptoms 40 examples are accepted in test example 6, outpatient service for medical treatment; tangible rhinorrhea, sneeze cold symptoms are arranged; and with symptoms such as laryngopharynx swelling and pain, heating, headaches, be divided into Radix Isatidis group, taurine group, CN1813849 group and of the present invention group, 10 cases of every test group respectively.
The Radix Isatidis group:
Medication: Radix Isatidis granule whenever comprises Radix Isatidis crude drug 14 grams.
The patient takes Radix Isatidis granule every day three times, each bag, add roxithromycin capsules (specification: 0.15 gram) 1, twice of every day.After taking medicine three days, have 5 example headaches, laryngopharynx swelling and pain symptom to take a turn for the better, have two examples due to illness feelings increase the weight of, change infusion treatment into, it is undesirable that 3 examples identify oneself effect, changes the clothes other drug.
The taurine group:
Medication: taurine particles whenever comprises taurine 0.8 gram.
The patient takes each two bags of taurine particles, adds moroxydine (moroxydine hydrochloride) simultaneously every day three times, after taking medicine three days, has 3 example headaches, laryngopharynx swelling and pain symptom to take a turn for the better, have 3 examples due to illness feelings increase the weight of, change the clothes other drug, 4 routine symptoms do not have the clothes of changing other drug.
The CN1813849 group:
The preparation of preparation:
Radix Isatidis 1400 grams decoct with water the back and filter, precipitation; getting upper strata filtrate, to be concentrated into relative density be 1.20 (50 ℃), adds ethanol and make that to contain the alcohol amount be 60%, staticly settles; get the upper strata stillness of night, be condensed into thick paste, add sucrose 300g and dextrin 300g; mix, add taurine 40 grams again, mix; granulate, dry back branch is filled to 100 bags, gets compositions and whenever comprises former medicine 14 grams of Radix Isatidis; taurine 0.4 gram, standby.
The patient takes said composition every day three times, each bag, and after taking medicine 3 days, 5 routine heatings, headache, laryngopharynx swelling and pain symptom take a turn for the better, and week recovery from illness continues to take medicine.5 routine symptoms do not have improvement, change the clothes other drug.
Of the present invention group: the patient takes the preparation of embodiment 10, every day three times, and each bag, 6 routine heatings after taking medicine 3 days, headache, laryngopharynx swelling and pain transference cure, 4 routine heatings, headache, laryngopharynx swelling and pain symptom take a turn for the better, and continue to take medicine and fully recover in 5 days.
By above contrast as can be seen, of the present invention group of curative effect is significantly better than other test group.
Claims (3)
1. combination of oral medication; it is characterized in that; contain Radix Isatidis extract granule 1.5 grams in the compositions of unit dose; taurine 1.5 grams, wherein the Radix Isatidis extract granule prepares by the following method: the 10kg Radix Isatidis decocts with water twice; 2 hours for the first time; 1 hour for the second time, filter decocting liquid twice, filtrate merges; being concentrated into relative density is 1.20 at 50 ℃; add ethanol and make content reach 60%, leave standstill and make precipitation, get the supernatant; reclaim ethanol and be concentrated into an amount of; add an amount of dextrin, make granule, obtain the 1kg extract particles.
2. combination of oral medication; it is characterized in that; contain Radix Isatidis extract granule 1.0 grams in the compositions of unit dose; taurine 1 gram, wherein the Radix Isatidis extract granule prepares by the following method: the 10kg Radix Isatidis decocts with water twice; 2 hours for the first time; 1 hour for the second time, filter decocting liquid twice, filtrate merges; being concentrated into relative density is 1.20 at 50 ℃; add ethanol and make content reach 60%, leave standstill and make precipitation, get the supernatant; reclaim ethanol and be concentrated into an amount of; add an amount of dextrin, make granule, obtain the 1kg extract particles.
3. combination of oral medication; it is characterized in that; contain Radix Isatidis extract granule 1.3 grams in the compositions of unit dose; taurine 1.3 grams, wherein the Radix Isatidis extract granule prepares by the following method: the 10kg Radix Isatidis decocts with water twice; 2 hours for the first time; 1 hour for the second time, filter decocting liquid twice, filtrate merges; being concentrated into relative density is 1.20 at 50 ℃; add ethanol and make content reach 60%, leave standstill and make precipitation, get the supernatant; reclaim ethanol and be concentrated into an amount of; add an amount of dextrin, make granule, obtain the 1kg extract particles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810016954 CN101606960B (en) | 2008-06-22 | 2008-06-22 | Oral medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810016954 CN101606960B (en) | 2008-06-22 | 2008-06-22 | Oral medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101606960A CN101606960A (en) | 2009-12-23 |
| CN101606960B true CN101606960B (en) | 2013-07-03 |
Family
ID=41480970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810016954 Expired - Fee Related CN101606960B (en) | 2008-06-22 | 2008-06-22 | Oral medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101606960B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614242B (en) * | 2012-04-13 | 2013-06-12 | 孙长海 | Dropping pill of isatis root and folium isatidis and preparing method thereof |
| CN102895484A (en) * | 2012-10-23 | 2013-01-30 | 河南亚卫动物药业有限公司 | Compound injection for clearing away heat and toxic materials and preparation method thereof |
| CN109125479A (en) * | 2018-11-09 | 2019-01-04 | 南京朗博特动物药业有限公司 | A kind of Chinese medicine composition and preparation method thereof for pet cat weakness type cold |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813849A (en) * | 2005-12-08 | 2006-08-09 | 王金政 | Medicine for treating common cold and its preparing method |
-
2008
- 2008-06-22 CN CN 200810016954 patent/CN101606960B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813849A (en) * | 2005-12-08 | 2006-08-09 | 王金政 | Medicine for treating common cold and its preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101606960A (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113521232B (en) | A Chinese medicinal composition containing Atractylodis rhizoma | |
| KR20220098360A (en) | Forsythia-Astragalus peritoneal preparation and its manufacturing method and use | |
| CN104887952B (en) | A composition with the effect of nourishing yin and moistening the lung and its preparation method and application | |
| CN101606960B (en) | Oral medicinal composition | |
| CN103920027A (en) | Medicament for treating acute jaundice hepatitis B and preparation method thereof | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN111184854A (en) | Chinese medicinal prescription for preventing virus infection | |
| CN101439069B (en) | Leaf extract of scutellaria chinensis, its preparation method and its application | |
| CN102641335A (en) | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof | |
| CN105381153A (en) | Traditional Chinese medicine preparation for treating bronchitis and preparation method thereof | |
| CN105343660A (en) | Traditional Chinese medicinal preparation for treating peripheral vertigo and preparation method of traditional Chinese medicinal preparation | |
| CN100525821C (en) | Chinese medicine for treating bed-wetting disease and its production | |
| CN116139237A (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN113521210B (en) | Chinese medicinal composition containing herba Moslae | |
| CN101322733A (en) | Chinese herbal medicine formulation for treating pollution lung disease | |
| CN111700974A (en) | Dendrobium yin nourishing and blood sugar reducing pill and preparation method thereof | |
| CN113521206B (en) | Traditional Chinese medicine composition containing burdock | |
| CN102631496B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN101745093A (en) | Medicine for quickly treating infantile chronic diarrhea | |
| CN102631486B (en) | Health care composition | |
| CN102783645B (en) | Health care product for enhancing immunity | |
| CN101829185B (en) | Medicinal composition for resisting influenza virus | |
| CN1259964C (en) | Medicine for treating and preventing chronic obstructive pulmonary disease | |
| CN105664048A (en) | Pharmaceutical composition inhibiting gastric cancer cell proliferation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: DISHA PHARMACEUTICAL GROUP SHANDONG DISHA PHARMACE Free format text: FORMER OWNER: WEIHAI WEITAI PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 264205 NO. 55, QILU AVENUE, ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, WEIHAI CITY, SHANDONG PROVINCE TO: 264200 NO. 1, QINGDAO SOUTH ROAD, ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, WEIHAI CITY, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110513 Address after: 264200 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant after: Disha Pharmaceutical Industry Group Corp., Ltd. Co-applicant after: Disha Pharmaceutical Group Shandong Disha Pharmaceutical Co., Ltd. Co-applicant after: Weihai Disu Pharmaceutical Co., Ltd. Co-applicant after: Weihai Weitai Medical Technology Development Co., Ltd. Address before: 264205 No. 55 Qilu Road, Weihai economic and Technological Development Zone, Shandong Applicant before: Disha Pharmaceutical Industry Group Corp., Ltd. Co-applicant before: Weihai Weitai Medical Technology Development Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130703 Termination date: 20140622 |
|
| EXPY | Termination of patent right or utility model |